Get Our Top Trade Ideas Delivered Daily - 65% Off Now

+ New Watchlist

Benzinga Research

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise

Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs

Free Benzinga Pro Trial

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Dividend Calendar

Earnings Calendar

Economic Calendar

Guidance Calendar

Stock Split Calendar

Trade Ideas

Free Stock Reports

Trade Idea Feed

Analyst Ratings

Unusual Options Activity

Free Newsletter

Government Trades

Short Interest

Largest Increase

Largest Decrease

Calculators

Margin Calculator

Forex Profit Calculator

100x Options Profit Calculator

Comments

Loading...

Bristol-Myers Squibb

BMYNYSE

Logo brought to you by Benzinga Data

Perks Buy Compare Brokers

Perks Buy Compare Brokers

$49.41

0.390.80%

At Close: -

$49.42

0.010.02%

After Hours: Sep 20, 7:27 PM EDT

15 minutes delayed

The dividend Ex-Date is in 11 days

Bristol-Myers Squibb (BMY) Forecast

News

Earnings Guidance Dividends Analyst Ratings Insider Trades Government Trades Short Interest

Latest news for Bristol-Myers Squibb (NYSE:BMY) Stock

Bristol-Myers Squibb Stock (NYSE: BMY)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Friday, September 20, 2024

Bristol-Myers Acquired Drug KarXT Poised For FDA Approval As First New Type Of Schizophrenia Treatment In 70 Years
Vandana Singh

Wednesday, September 18, 2024

Bristol Myers Squibb Presents Data For Multiple Sclerosis Drug Zeposia, Shows Long-Term Efficacy
Vandana Singh
Bristol Myers Says New Data From Phase 3 DAYB...
Benzinga Newsdesk

Monday, September 16, 2024

What Analysts Are Saying About Bristol-Myers Squibb Stock
Benzinga Insights
Cantor Fitzgerald Reiterates Neutral on Brist...
Benzinga Newsdesk
Immatics Presented The Proof-of-concept Clini...
Benzinga Newsdesk
Reported Sunday, Bristol Myers Squibb's Check...
Benzinga Newsdesk

Thursday, September 12, 2024

Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF?
Zacks

Tuesday, September 10, 2024

Bernie Sanders Says If You're Poor In America You'll Live 10-15 Years Less: 'Anybody Else See A Problem With That?'
Benzinga Neuro

Monday, September 09, 2024

Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst
Vandana Singh

Friday, September 06, 2024

FDA Battles Backlog of Drug Factory Inspections Since COVID-19
Vandana Singh

Tuesday, September 03, 2024

Despite Medicare Negotiations, Americans May Still Have To Pay More For Prescription Drugs
Vandana Singh
Reported Earlier, Bristol Myers Squibb Presen...
Benzinga Newsdesk

Friday, August 30, 2024

Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
Chris Katje

Wednesday, August 28, 2024

Jefferies Maintains Hold on Bristol-Myers Squ...
Benzinga Newsdesk
As Regulators Gear Up To Decide On Bristol Myers' Schizophrenia Treatment, Neurocrine Biosciences' Data Disappoints Investors
Vandana Singh
Kohl's Posts Upbeat Q2 Earnings, Joins Box, Waldencast, AeroVironment And Other Big Stocks Moving Higher On Wednesday
Avi Kapoor

Tuesday, August 27, 2024

Regulators Expected To Approve Innovative Schizophrenia Treatment From Bristol Myers, Karuna
Anthony Noto
Market Whales and Their Recent Bets on BMY Options
Benzinga Insights

Monday, August 26, 2024

Bristol Myers Squibb To Present New Findings ...
Benzinga Newsdesk

Friday, August 23, 2024

Cancer Medicines From Merck, Bristol Myers And BeiGene In Question, As FDA Committee To Discuss Limiting PD-1 Drugs For Stomach Cancer
Vandana Singh

Thursday, August 22, 2024

Bristol Myers' HCC Combo Drug Accepted for FDA Review
Zacks
Bristol-Myers Squibb Says FDA Schedules Oncol...
Benzinga Newsdesk
Bristol-Myers Squibb shares are trading lower...
Benzinga Newsdesk
Key Takeaways From Bristol-Myers Squibb Analyst Ratings
Benzinga Insights
Barclays Maintains Underweight on Bristol-Mye...
Benzinga Newsdesk

Wednesday, August 21, 2024

Bristol-Myers Squibb's Options Frenzy: What You Need to Know
Benzinga Insights
The FDA Has Accepted Bristol Myers Squibb's S...
Benzinga Newsdesk

Monday, August 19, 2024

EMA Validates Bristol Myers Squibb's Applicat...
Benzinga Newsdesk

Friday, August 16, 2024

Check Out What Whales Are Doing With BMY
Benzinga Insights

Thursday, August 15, 2024

Biden Administration Targets $6B Savings Through Medicare Drug Price Negotiations
Vandana Singh

Wednesday, August 14, 2024

Pharma ETFs in Focus Post Solid Q2 Earnings
Zacks
Bristol Myers' German Partner Evotec Plans Layoffs, Cites 'Challenging Revenues, Profitability'
Vandana Singh
Evotec Rises 12% on $75M Milestone Payment From BMY
Zacks

Tuesday, August 13, 2024

Cancer-Focused Syros Pharmaceuticals Stops Mid-Stage Leukemia Combo Therapy Study, Cites Disappointing Unexpected Outcome
Vandana Singh
Evotec And Bristol Myers Squibb Expand Molecu...
Benzinga Newsdesk

Monday, August 12, 2024

TD Cowen Maintains Hold on Bristol-Myers Squi...
Benzinga Newsdesk

Friday, August 09, 2024

Smart Money Is Betting Big In BMY Options
Benzinga Insights

Thursday, August 08, 2024

Evotec Advances Strategic Neuroscience Partne...
Benzinga Newsdesk

Tuesday, August 06, 2024

Smart Money Is Betting Big In BMY Options
Benzinga Insights

Monday, August 05, 2024

Bristol Myers Squibb Terminates Cancer Drug Development Program With Agenus
Vandana Singh

Thursday, August 01, 2024

8 Health Care Stocks With Whale Alerts In Today's Session
Benzinga Insights

Tuesday, July 30, 2024

Post-it Manufacturer 3M Sticks Landing While Ford Tanks: Biggest Beats And Misses From Earnings Season So Far
Hayden Buckfire
Bristol Myers, Johnson & Johnson, AbbVie, AstraZeneca Expect Minimal Impact From Upcoming Medicare Price Negotiations
Vandana Singh
10 Health Care Stocks Whale Activity In Today's Session
Benzinga Insights
CNBC Halftime Report Final Trades: Bristol-My...
Benzinga Newsdesk
Pfizer Records First Sales Growth In Its Post-Covid Era And It Owes It To Cancer
Upwallstreet
Market Momentum: Your Weekly Financial Forecast
Volumeleaders.com
Pfizer Exec Says Shares Bristol Myers' View T...
Benzinga Newsdesk

Monday, July 29, 2024

Is Bristol-Myers Squibb's Stock Rally Justified? Bull Vs. Bear Analysts On Q2 Earnings
Priya Nigam

Create a Watchlist

FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.

People Also Watch

Popular Channels

PreMarket Prep
Press Releases
Analyst Ratings
News
Options
ETFs

Tools & Features

Real Time Feed
Public RSS Feeds
Submit News Tips
Blog
Embeddable Finance Widgets & Tools
Benzinga Catalyst

Partners & Contributors

Affiliate Program
Contributor Portal
Licensing & Syndication
Sponsored Content
Advertise With Us
Lead Generation & SEO

About Benzinga

About Us
Careers
In The News
Events
Contact Us

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap

© 2024 Benzinga | All Rights Reserved